Everest Medicines (Beijing) Co., Ltd.

1952 · HKEX

Public Market Listing

1952HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Everest Medicines (Beijing) Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
2Approved
4Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
IgA Nephropathy
etrasimod(Velsipity)
Approved
S1P receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Lerodalcibep(Lerochol)
Phase 3
PCSK9Protein / enzyme therapeutic
Atherosclerotic Cardiovascular Disease
Phase 3
CaSR; OGPPeptide
Chronic Kidney Disease
Secondary Hyperparathyroidism
Phase 3
CD20Monoclonal antibody
Systemic Lupus ErythematosusFollicular LymphomaPrimary Membranous Nephropathy
Phase 3
P2Y12 platelet receptorSmall molecule
Atherosclerotic Cardiovascular Disease
Phase 1/2
Multiple tumor-associated antigensVaccine
Non-Small Cell Lung Cancer

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
MT1013Phase 3Secondary Hyperparathyroidism, Chronic Kidney Disease
Est. primary completion 2026-11-26 · NCT07122401 · CT.gov ↗
What to watch
December 2026 (1)
SumecigrelPhase 3Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Est. primary completion 2026-12-30 · NCT06577519 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Lerodalcibep · LerocholPhase 3Familial Hypercholesterolemia - Heterozygous
Est. primary completion 2028-07-31 · NCT07102511 · CT.gov ↗
What to watch
December 2028 (1)
Obinutuzumab beta (Bejescin)Phase 3Systemic Lupus Erythematosus
Est. primary completion 2028-12 · NCT07405970 · CT.gov ↗
What to watch
2029 (3)
June 2029 (2)
etrasimod · VelsipityPhase 2Ulcerative Colitis
Est. primary completion 2029-06-16 · NCT05287126 · CT.gov ↗
What to watch
etrasimod · VelsipityPhase 3Ulcerative Colitis
Est. primary completion 2029-06-19 · NCT03950232 · CT.gov ↗
What to watch
November 2029 (1)
EVM14Phase 1/2Selected Types of Solid Tumor
Est. primary completion 2029-11 · NCT07095868 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
etrasimod · VelsipityPhase 2Colitis, Ulcerative
Est. primary completion 2030-09-08 · NCT07470879 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Lerodalcibep · LerocholPhase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2031-07-31 · NCT07775339 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2026Topline resultSumecigrel (formerly vicagrel)Vcare reports completed Phase III studies of Sumecigrel versus clopidogrel
China · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗
26 June 2026Filing acceptedLerodalcibepNMPA accepts the LEROCHOL (lerodalcibep) BLA for hypercholesterolemia
CN, NMPA · Everest Medicines · Source ↗
4 June 2026Priority reviewObinutuzumab beta (Bejescin)NMPA marketing application for obinutuzumab beta (Bejescin) in primary membranous nephropathy under priority review (reported 2026-06-04)
CN, NMPA · Beijing Mabworks Biotech · Source ↗
Q2 2026Filing acceptedSumecigrel (formerly vicagrel)NMPA accepts NDA for Sumecigrel Capsule (formerly vicagrel)
China, NMPA · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.